Orbimed Capital LLC is Director at Repare Therapeutics Inc. (RPTX). They have made 4 open-market trades across 4 companies since 2020, most recently 2024-08-22.
CIK 0001157524
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $5.0M since 2023, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRY | SELL | 2024-08-22 | 2024-08-23 | $12.94 | $5.1M | -10.4% | +7.5% | +2.1% |
| PRLD | BUY | 2023-05-22 | 2023-05-24 | $5.75 | $5.0M | +2.7% | -15.5% | -40.6% |
| ARQT | SELL | 2022-04-06 | 2022-04-08 | $20.68 | $25.4M | -3.0% | -9.6% | +10.1% |
| RPTX | SELL · 10b5-1 | 2021-08-26 | 2021-08-30 | $34.15 | $395K | -4.3% | -23.3% | -27.6% |
| RPTX | SELL · 10b5-1 | 2021-08-23 | 2021-08-25 | $34.17 | $622K | -8.4% | -19.3% | -26.0% |
| ALEC | SELL | 2020-01-09 | 2020-01-13 | $19.50 | $13.0M | +39.8% | +72.3% | +31.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.